The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study

<p>The efficacy variables during 12 weeks of Shinbaro treatment. (a)<i> Migraine frequency</i>. (b)<i> Rescue medications frequency</i>. (c)<i> MIDAS</i> (d)<i> Serum CGRP concentration measured in pg/mL</i>.<i> P</i>-values in italic were obtained from the one-way repeated measures ANOVA. The migraine frequency decreased time-dependently (<i>P</i> =0.003), whereas changes to the rescue medications frequency and the MIDAS score were not time-dependent (<i>P</i> &gt; 0.05). The paired t-tests showed that differences of the means were significant at <svg height="6.11511pt" id="M11" style="vertical-align:-0.04980993pt" version="1.1" viewbox="-0.0498162 -6.0653 8.13767 6.11511" width="8.13767pt" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M485 147C487 173 478 200 466 219C419 224 389 226 342 249C389 272 419 273 465 279C479 297 489 321 485 351C463 366 435 372 413 371C385 332 369 308 325 278C329 331 342 357 361 401C352 421 336 442 308 453C285 442 265 421 255 401C274 357 287 331 291 278C248 308 232 333 203 370C181 372 155 369 131 351C129 325 138 298 150 279C198 274 227 272 274 249C227 226 197 225 151 219C138 201 127 177 131 147C153 132 181 126 204 127C231 166 248 190 291 220C287 167 274 141 256 97C265 77 280 56 308 45C331 56 351 77 361 97C342 141 329 167 325 220C369 190 385 165 413 128C435 126 461 129 485 147Z"></path></g></svg><i> P</i> &lt; 0.05, <svg height="6.11511pt" id="M12" style="vertical-align:-0.04980993pt" version="1.1" viewbox="-0.0498162 -6.0653 16.1757 6.11511" width="16.1757pt" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M485 147C487 173 478 200 466 219C419 224 389 226 342 249C389 272 419 273 465 279C479 297 489 321 485 351C463 366 435 372 413 371C385 332 369 308 325 278C329 331 342 357 361 401C352 421 336 442 308 453C285 442 265 421 255 401C274 357 287 331 291 278C248 308 232 333 203 370C181 372 155 369 131 351C129 325 138 298 150 279C198 274 227 272 274 249C227 226 197 225 151 219C138 201 127 177 131 147C153 132 181 126 204 127C231 166 248 190 291 220C287 167 274 141 256 97C265 77 280 56 308 45C331 56 351 77 361 97C342 141 329 167 325 220C369 190 385 165 413 128C435 126 461 129 485 147Z"></path></g><g transform="matrix(.013,0,0,-0.013,8.038,0)"><path d="M485 147C487 173 478 200 466 219C419 224 389 226 342 249C389 272 419 273 465 279C479 297 489 321 485 351C463 366 435 372 413 371C385 332 369 308 325 278C329 331 342 357 361 401C352 421 336 442 308 453C285 442 265 421 255 401C274 357 287 331 291 278C248 308 232 333 203 370C181 372 155 369 131 351C129 325 138 298 150 279C198 274 227 272 274 249C227 226 197 225 151 219C138 201 127 177 131 147C153 132 181 126 204 127C231 166 248 190 291 220C287 167 274 141 256 97C265 77 280 56 308 45C331 56 351 77 361 97C342 141 329 167 325 220C369 190 385 165 413 128C435 126 461 129 485 147Z"></path></g></svg><i> P</i> &lt;0.01, and <svg height="6.11511pt" id="M13" style="vertical-align:-0.04980993pt" version="1.1" viewbox="-0.0498162 -6.0653 30.0247 6.11511" width="30.0247pt" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M485 147C487 173 478 200 466 219C419 224 389 226 342 249C389 272 419 273 465 279C479 297 489 321 485 351C463 366 435 372 413 371C385 332 369 308 325 278C329 331 342 357 361 401C352 421 336 442 308 453C285 442 265 421 255 401C274 357 287 331 291 278C248 308 232 333 203 370C181 372 155 369 131 351C129 325 138 298 150 279C198 274 227 272 274 249C227 226 197 225 151 219C138 201 127 177 131 147C153 132 181 126 204 127C231 166 248 190 291 220C287 167 274 141 256 97C265 77 280 56 308 45C331 56 351 77 361 97C342 141 329 167 325 220C369 190 385 165 413 128C435 126 461 129 485 147Z"></path></g><g transform="matrix(.013,0,0,-0.013,10.944,0)"><path d="M485 147C487 173 478 200 466 219C419 224 389 226 342 249C389 272 419 273 465 279C479 297 489 321 485 351C463 366 435 372 413 371C385 332 369 308 325 278C329 331 342 357 361 401C352 421 336 442 308 453C285 442 265 421 255 401C274 357 287 331 291 278C248 308 232 333 203 370C181 372 155 369 131 351C129 325 138 298 150 279C198 274 227 272 274 249C227 226 197 225 151 219C138 201 127 177 131 147C153 132 181 126 204 127C231 166 248 190 291 220C287 167 274 141 256 97C265 77 280 56 308 45C331 56 351 77 361 97C342 141 329 167 325 220C369 190 385 165 413 128C435 126 461 129 485 147Z"></path></g><g transform="matrix(.013,0,0,-0.013,21.887,0)"><path d="M485 147C487 173 478 200 466 219C419 224 389 226 342 249C389 272 419 273 465 279C479 297 489 321 485 351C463 366 435 372 413 371C385 332 369 308 325 278C329 331 342 357 361 401C352 421 336 442 308 453C285 442 265 421 255 401C274 357 287 331 291 278C248 308 232 333 203 370C181 372 155 369 131 351C129 325 138 298 150 279C198 274 227 272 274 249C227 226 197 225 151 219C138 201 127 177 131 147C153 132 181 126 204 127C231 166 248 190 291 220C287 167 274 141 256 97C265 77 280 56 308 45C331 56 351 77 361 97C342 141 329 167 325 220C369 190 385 165 413 128C435 126 461 129 485 147Z"></path></g></svg><i> P</i> &lt;0.001 significance levels. Per protocol analysis,<i> n</i> =37.</p>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study 